Background Neuroprognostication after pediatric out-of-hospital cardiac arrest (OHCA) is challenging. Serum lactate has potential as an adjunct biomarker. We examined the association of lactate measurements with 12-month neurobehavioral outcomes and hospital mortality in a secondary analysis of the Therapeutic Hypothermia After Pediatric Cardiac Arrest Out-of-Hospital (THAPCA-OH) trial. Methods Study participants with at least one lactate measurement (mmol/L) within 24-hours of return of spontaneous circulation (ROSC) were included. The primary outcome was unfavorable neurobehavioral functioning or death at 12-months. Univariable, multivariable and area under the receiver operator characteristic curve (AUROC) analyses were performed at four timepoints: first lactate within 6 or 12-hours, and peak lactate within 12 or 24-hours of ROSC. Results The primary analysis included 213 patients, 82% of which had a primary unfavorable outcome. AUROCs showed strong association of lactate with all outcomes and were similar between timepoints, thus we reported the analyses of first lactate within 6 hours of ROSC. Median lactate measurements were higher among those with primary unfavorable versus favorable 12-month outcome (7.8 versus 3.1, difference95%CI: 4.83.7-5.9) and those who died in the hospital versus survivors (8.6 versus 3.6, difference95%CI: 5.14.0-6.1). For each lactate increase of 1 mmol/L, odds (95%CI) of primary unfavorable outcome at 12-months increased 1.40 (1.17, 1.69). Conclusion Among subjects enrolled in the THAPCA-OH trial, higher lactates within 6-hours of ROSC were associated with unfavorable outcome at one year. Lactate has potential as an adjunct for early neuroprognostication and mortality prediction.
Schmidt et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: